Afrezza denied as non-formulary by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Afrezza as Non-Formulary

Humana places Afrezza (inhaled insulin) outside its standard formulary on most plan designs, meaning the drug either has no tier assignment or is assigned to an exclusion tier that requires a separate formulary exception before the plan will cover it. This denial is administrative rather than clinical — it reflects a coverage structure decision, not a judgment about your individual medical situation.

## Why This Denial Is Appealable

Non-formulary status does not mean the drug is uncoverable. Federal law requires plans to maintain a formulary exception process, and both ACA-regulated and ERISA-governed plans must consider whether a non-formulary drug is medically necessary for a specific patient when alternatives on the formulary are clinically inappropriate. Under ACA Section 2719 you retain the right to internal appeal and then independent external review. The external-review window is typically around four months from the final internal denial, and an expedited track is available when health could be seriously jeopardized by delay.

## The Formulary Exception Argument

The strongest path for Afrezza non-formulary denials is a formulary exception grounded in medical necessity. To build that case:

1. Identify the formulary alternatives Humana designated. The denial letter or Humana's drug formulary (available on Humana.com) will name the covered insulin products. List each one.

2. Document why each formulary alternative is clinically inappropriate or has failed. For each listed alternative, the prescriber must explain — supported by chart documentation — why that product does not meet this patient's clinical needs. Reasons that carry weight include documented adverse effects, recurrent hypoglycemia with injectable formulations, injection-site complications, a pulmonary or other condition affecting injectable delivery, or other individualized clinical factors.

3. Tie the exception request to Humana's own exception criteria. Request Humana's formulary exception policy and coverage criteria in writing. Map the prescriber's clinical rationale directly to the language of those criteria.

4. Confirm FDA label eligibility. Verify with the prescriber that the patient meets every criterion in the FDA-approved prescribing information for Afrezza and document this in the exception request.

5. Include a prescriber attestation letter. The letter should be specific: it should name each formulary alternative, state why each is inadequate for this patient, and explain why Afrezza is medically necessary — not merely preferred.

## What to Submit

• Written request for formulary exception (use Humana's form if one exists, but a prescriber letter is always required)
• Humana's published formulary and exception criteria (request the version current on the date of denial)
• FDA prescribing label for Afrezza
• Chart documentation of prior insulin trials with dates and outcomes
• Prescriber's individualized medical-necessity and clinical-inadequacy letter
• Relevant clinical notes, lab results, and medication history

## Timeline

• Formulary exception / internal appeal: Timeframe is stated on the denial notice; typically 30 days for standard review, 72 hours expedited.
• External review: Available after exhausting internal options; request within approximately four months of final denial. An IRO reviews on clinical grounds, independently of Humana's formulary decisions.